Symbols / TVTX Stock $42.84 -1.54% Travere Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
TVTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Eric M. Dube Ph.D.
Exch · Country NGM · United States
Market Cap 3.98B
Enterprise Value 4.11B
Income -45.64M
Sales 536.20M
FCF (ttm) -51.17M
Book/sh 1.26
Cash/sh 2.85
Employees 497
Insider 10d —
IPO Nov 08, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 8.56
PEG —
P/S 7.43
P/B 33.92
P/C —
EV/EBITDA 255.41
EV/Sales 7.66
Quick Ratio 2.82
Current Ratio 3.13
Debt/Eq 331.88
LT Debt/Eq —
EPS (ttm) -0.50
EPS next Y 5.01
EPS Growth —
Revenue Growth 55.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-04
Earnings (prior) 2026-05-04
ROA -6.46%
ROE -69.38%
ROIC —
Gross Margin 55.95%
Oper. Margin -29.02%
Profit Margin -4.00%
Shs Outstand 92.99M
Shs Float 91.98M
Insider Own 0.76%
Instit Own 115.00%
Short Float 19.99%
Short Ratio 5.44
Short Interest 14.22M
52W High 48.61
vs 52W High -11.87%
52W Low 13.88
vs 52W Low 208.65%
Beta 1.14
Impl. Vol. 58.50%
Rel Volume 0.82
Avg Volume 2.13M
Volume 1.74M
Target (mean) $53.57
Tgt Median $54.50
Tgt Low $43.00
Tgt High $60.00
# Analysts 14
Recom Strong_buy
Prev Close $43.51
Price $42.84
Change -1.54%
About

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$53.57
Mean price target
2. Current target
$42.84
Latest analyst target
3. DCF / Fair value
$-9.90
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$42.84
Low
$43.00
High
$60.00
Mean
$53.57

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-06 main Wells Fargo Overweight → Overweight $50
2026-05-05 main TD Cowen Buy → Buy $60
2026-05-05 main Citigroup Buy → Buy $59
2026-05-05 main Wedbush Outperform → Outperform $55
2026-05-05 main HC Wainwright & Co. Buy → Buy $57
2026-04-24 main Guggenheim Buy → Buy $56
2026-04-14 main Citigroup Buy → Buy $53
2026-04-14 main Canaccord Genuity Buy → Buy $56
2026-04-14 main Wedbush Outperform → Outperform $44
2026-04-14 main Guggenheim Buy → Buy $54
2026-04-14 reit HC Wainwright & Co. Buy → Buy $47
2026-03-25 main JP Morgan Overweight → Overweight $41
2026-02-06 main Piper Sandler Neutral → Neutral $38
2025-11-28 reit HC Wainwright & Co. Buy → Buy $47
2025-11-04 main Piper Sandler Neutral → Neutral $35
2025-10-31 main TD Cowen Buy → Buy $40
2025-09-19 reit HC Wainwright & Co. Buy → Buy $47
2025-09-12 main Stifel Hold → Hold $25
2025-09-11 main Wells Fargo Overweight → Overweight $35
2025-09-10 reit HC Wainwright & Co. Buy → Buy $47
News
RSS: Latest TVTX news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
490.73
+110.45%
233.18
+60.55%
145.24
+32.69%
109.46
Operating Revenue
490.73
+110.45%
233.18
+60.55%
145.24
+32.69%
109.46
Cost Of Revenue
10.34
+33.51%
7.74
-32.37%
11.45
+159.05%
4.42
Reconciled Cost Of Revenue
10.34
+33.51%
7.74
-32.37%
11.45
+159.05%
4.42
Gross Profit
480.39
+113.10%
225.43
+68.50%
133.79
+27.37%
105.04
Operating Expense
543.21
-0.66%
546.82
+7.11%
510.53
+20.17%
424.85
Research And Development
206.01
-27.13%
282.70
+15.39%
244.99
+7.77%
227.33
Selling General And Administration
337.20
+27.67%
264.12
-0.54%
265.54
+34.44%
197.52
General And Administrative Expense
337.20
+27.67%
264.12
-0.54%
265.54
+34.44%
197.52
Other Gand A
337.20
+27.67%
264.12
-0.54%
265.54
+34.44%
197.52
Total Expenses
553.55
-0.18%
554.56
+6.24%
521.98
+21.60%
429.27
Operating Income
-62.82
+80.45%
-321.39
+14.69%
-376.74
-17.80%
-319.81
Total Operating Income As Reported
-62.82
+80.60%
-323.83
+16.57%
-388.14
-21.36%
-319.81
EBITDA
22.22
+108.36%
-265.77
+18.54%
-326.25
-8.96%
-299.42
Normalized EBITDA
22.22
+108.44%
-263.33
+16.36%
-314.85
-7.88%
-291.84
Reconciled Depreciation
60.74
+39.46%
43.55
+13.04%
38.53
+85.96%
20.72
EBIT
-38.52
+87.55%
-309.33
+15.20%
-364.78
-13.94%
-320.14
Total Unusual Items
0.00
+100.00%
-2.44
+78.60%
-11.39
-50.36%
-7.58
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-2.44
+78.60%
-11.39
-50.36%
-7.58
Special Income Charges
0.00
+100.00%
-2.44
+78.60%
-11.39
-50.36%
-7.58
Other Special Charges
—
—
—
7.58
Impairment Of Capital Assets
—
—
—
—
Restructuring And Mergern Acquisition
0.00
-100.00%
2.44
-78.60%
11.39
0.00
Write Off
—
—
—
—
Net Income
-25.55
+92.06%
-321.55
-188.64%
-111.40
+60.00%
-278.48
Pretax Income
-49.27
+84.63%
-320.51
+14.78%
-376.11
-13.58%
-331.15
Net Non Operating Interest Income Expense
1.97
-70.26%
6.63
-36.41%
10.43
+320.22%
-4.74
Interest Expense Non Operating
10.75
-3.88%
11.18
-1.34%
11.33
+2.91%
11.01
Net Interest Income
1.97
-70.26%
6.63
-36.41%
10.43
+320.22%
-4.74
Interest Expense
10.75
-3.88%
11.18
-1.34%
11.33
+2.91%
11.01
Interest Income Non Operating
12.72
-28.60%
17.82
-18.15%
21.77
+246.85%
6.28
Interest Income
12.72
-28.60%
17.82
-18.15%
21.77
+246.85%
6.28
Other Income Expense
11.58
+301.15%
-5.76
+41.27%
-9.80
-48.39%
-6.60
Other Non Operating Income Expenses
11.58
+448.95%
-3.32
-308.16%
1.59
+63.66%
0.97
Tax Provision
0.99
+723.33%
0.12
-46.19%
0.22
-28.75%
0.31
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.51
+78.60%
-2.39
-50.36%
-1.59
Net Income Including Noncontrolling Interests
-25.55
+92.06%
-321.55
-188.64%
-111.40
+60.00%
-278.48
Net Income From Continuing Operation Net Minority Interest
-50.26
+84.32%
-320.63
+14.80%
-376.33
-13.54%
-331.47
Net Income From Continuing And Discontinued Operation
-25.55
+92.06%
-321.55
-188.64%
-111.40
+60.00%
-278.48
Net Income Continuous Operations
-50.26
+84.32%
-320.63
+14.80%
-376.33
-13.54%
-331.47
Net Income Discontinuous Operations
24.71
+2801.09%
-0.92
-100.35%
264.93
+400.01%
52.99
Normalized Income
-50.26
+84.23%
-318.70
+13.24%
-367.33
-12.86%
-325.48
Net Income Common Stockholders
-25.55
+92.06%
-321.55
-188.64%
-111.40
+60.00%
-278.48
Diluted EPS
-0.29
+92.89%
-4.08
-172.00%
-1.50
+65.68%
-4.37
Basic EPS
-0.29
+92.89%
-4.08
-172.00%
-1.50
+65.68%
-4.37
Basic Average Shares
89.21
+13.09%
78.89
+6.22%
74.27
+16.48%
63.76
Diluted Average Shares
89.21
+13.09%
78.89
+6.22%
74.27
+16.48%
63.76
Diluted NI Availto Com Stockholders
-25.55
+92.06%
-321.55
-188.64%
-111.40
+60.00%
-278.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
605.19
+1.86%
594.12
-24.69%
788.91
+17.30%
672.59
Current Assets
437.56
+5.01%
416.70
-32.44%
616.77
+26.79%
486.44
Cash Cash Equivalents And Short Term Investments
322.80
-12.92%
370.70
-34.60%
566.85
+25.90%
450.25
Cash And Cash Equivalents
93.03
+58.94%
58.53
+0.62%
58.18
-5.69%
61.69
Other Short Term Investments
229.76
-26.40%
312.17
-38.63%
508.68
+30.91%
388.56
Receivables
80.13
+195.52%
27.12
+28.03%
21.18
+27.23%
16.65
Accounts Receivable
80.13
+195.52%
27.12
+28.03%
21.18
+27.23%
16.65
Taxes Receivable
—
—
—
—
Inventory
5.88
-5.24%
6.20
-34.11%
9.41
+108.05%
4.52
Raw Materials
—
—
—
2.40
Work In Process
—
—
—
0.00
Finished Goods
—
—
—
2.13
Prepaid Assets
—
—
—
—
Assets Held For Sale Current
—
—
0.00
-100.00%
2.99
Other Current Assets
28.76
+126.72%
12.69
-34.39%
19.34
+60.68%
12.03
Total Non Current Assets
166.87
-5.55%
176.67
+2.60%
172.19
-7.52%
186.19
Net PPE
14.60
-25.64%
19.63
-23.14%
25.54
-15.01%
30.05
Gross PPE
24.70
-13.00%
28.39
-13.94%
32.98
-6.42%
35.24
Accumulated Depreciation
-10.10
-15.34%
-8.76
-17.63%
-7.44
-43.27%
-5.20
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
10.58
-26.02%
14.29
-20.85%
18.06
-14.00%
21.00
Machinery Furniture Equipment
5.13
+8.62%
4.72
-6.72%
5.06
+1.48%
4.99
Construction In Progress
—
0.00
-100.00%
0.17
+119.48%
0.08
Other Properties
—
—
—
—
Leases
8.99
-4.03%
9.37
-3.32%
9.69
+5.58%
9.18
Goodwill And Other Intangible Assets
113.11
+9.59%
103.22
-1.21%
104.49
+7.59%
97.12
Goodwill
—
0.80
+0.00%
0.80
+0.00%
0.80
Other Intangible Assets
113.11
+9.59%
103.22
-0.45%
103.69
+7.65%
96.32
Other Non Current Assets
39.16
-27.24%
53.82
+27.67%
42.16
-28.58%
59.03
Total Liabilities Net Minority Interest
490.36
-8.35%
535.05
-9.02%
588.10
-6.61%
629.73
Current Liabilities
159.90
-20.35%
200.75
+12.84%
177.91
+25.14%
142.16
Payables And Accrued Expenses
109.32
+46.94%
74.40
-43.10%
130.76
+68.15%
77.77
Payables
24.80
+5.38%
23.53
-43.53%
41.67
+141.04%
17.29
Accounts Payable
24.80
+5.38%
23.53
-43.53%
41.67
+141.04%
17.29
Other Payable
—
—
—
13.49
Current Accrued Expenses
84.52
+66.18%
50.86
-42.90%
89.08
+47.31%
60.48
Pensionand Other Post Retirement Benefit Plans Current
41.52
+18.05%
35.17
+17.58%
29.91
-15.20%
35.27
Current Debt And Capital Lease Obligation
5.88
-92.07%
74.08
+1409.13%
4.91
+10.74%
4.43
Current Debt
—
68.68
—
—
Other Current Borrowings
—
68.68
—
—
Current Capital Lease Obligation
5.88
+8.70%
5.41
+10.10%
4.91
+10.74%
4.43
Current Deferred Liabilities
—
2.81
-60.33%
7.10
-40.75%
11.98
Current Deferred Revenue
—
2.81
-60.33%
7.10
-40.75%
11.98
Other Current Liabilities
3.19
-81.33%
17.11
+226.64%
5.24
-58.84%
12.72
Total Non Current Liabilities Net Minority Interest
330.46
-1.15%
334.30
-18.50%
410.19
-15.87%
487.57
Liabilities Heldfor Sale Non Current
—
—
0.00
-100.00%
64.20
Long Term Debt And Capital Lease Obligation
322.86
-1.42%
327.50
-18.10%
399.88
-0.79%
403.06
Long Term Debt
311.72
+0.46%
310.31
-17.75%
377.26
+0.46%
375.55
Long Term Capital Lease Obligation
11.13
-35.23%
17.19
-23.97%
22.61
-17.80%
27.51
Non Current Deferred Liabilities
—
—
1.83
-83.21%
10.93
Non Current Deferred Revenue
—
—
1.83
-83.21%
10.93
Other Non Current Liabilities
7.60
+11.85%
6.80
-34.15%
10.32
+9.96%
9.38
Stockholders Equity
114.83
+94.37%
59.08
-70.58%
200.81
+368.62%
42.85
Common Stock Equity
114.83
+94.37%
59.08
-70.58%
200.81
+368.62%
42.85
Capital Stock
0.01
+0.00%
0.01
+28.57%
0.01
+16.67%
0.01
Common Stock
0.01
+0.00%
0.01
+28.57%
0.01
+16.67%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
90.92
+3.97%
87.45
+16.04%
75.37
+17.23%
64.29
Ordinary Shares Number
90.92
+3.97%
87.45
+16.04%
75.37
+17.23%
64.29
Additional Paid In Capital
1,588.72
+5.47%
1,506.32
+13.44%
1,327.88
+25.27%
1,059.97
Retained Earnings
-1,472.71
-1.77%
-1,447.17
-28.57%
-1,125.62
-10.98%
-1,014.22
Gains Losses Not Affecting Retained Earnings
-1.19
-1386.25%
-0.08
+94.51%
-1.46
+49.91%
-2.91
Other Equity Adjustments
-1.19
-1386.25%
-0.08
+94.51%
-1.46
+49.91%
-2.91
Total Equity Gross Minority Interest
114.83
+94.37%
59.08
-70.58%
200.81
+368.62%
42.85
Total Capitalization
426.55
+15.48%
369.39
-36.10%
578.07
+38.16%
418.40
Working Capital
277.66
+28.58%
215.95
-50.79%
438.87
+27.48%
344.27
Invested Capital
426.55
-2.63%
438.06
-24.22%
578.07
+38.16%
418.40
Total Debt
328.73
-18.14%
401.58
-0.79%
404.78
-0.66%
407.49
Net Debt
218.69
-31.76%
320.45
+0.43%
319.09
+1.67%
313.86
Capital Lease Obligations
17.01
-24.73%
22.60
-17.90%
27.52
-13.84%
31.94
Net Tangible Assets
1.71
+103.88%
-44.14
-145.83%
96.32
+277.49%
-54.27
Tangible Book Value
1.71
+103.88%
-44.14
-145.83%
96.32
+277.49%
-54.27
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
37.78
+115.91%
-237.47
+15.19%
-280.02
-50.31%
-186.29
Cash Flow From Continuing Operating Activities
37.78
+116.43%
-230.02
+29.30%
-325.36
-24.73%
-260.85
Cash From Discontinued Operating Activities
0.00
+100.00%
-7.45
-116.44%
45.34
-39.19%
74.56
Net Income From Continuing Operations
-50.26
+84.32%
-320.63
+14.80%
-376.33
-13.54%
-331.47
Depreciation Amortization Depletion
60.74
+39.46%
43.55
+13.04%
38.53
+85.96%
20.72
Depreciation And Amortization
60.74
+39.46%
43.55
+13.04%
38.53
+85.96%
20.72
Other Non Cash Items
0.18
-99.76%
74.87
+4024.21%
-1.91
-164.29%
2.97
Stock Based Compensation
44.87
+21.55%
36.91
-16.57%
44.25
+16.00%
38.14
Provisionand Write Offof Assets
0.68
-75.74%
2.82
-7.24%
3.04
+192.49%
1.04
Asset Impairment Charge
—
—
—
—
Operating Gains Losses
—
—
—
7.58
Change In Working Capital
-14.00
+77.79%
-63.02
-147.38%
-25.48
-3011.43%
0.88
Change In Receivables
-26.97
-346.43%
-6.04
+46.53%
-11.30
-687.94%
-1.43
Changes In Account Receivables
-27.82
-363.62%
-6.00
+46.72%
-11.26
-962.64%
-1.06
Change In Inventory
5.02
+233.02%
-3.77
+90.43%
-39.42
-3160.55%
-1.21
Change In Prepaid Assets
-7.66
-142.04%
-3.16
+32.06%
-4.66
+10.37%
-5.20
Change In Payables And Accrued Expense
28.75
+159.14%
-48.62
-203.27%
47.08
+94.27%
24.24
Change In Accrued Expense
28.84
+192.85%
-31.06
-239.16%
22.32
+0.63%
22.18
Change In Payable
-0.09
+99.52%
-17.56
-170.92%
24.76
+1105.01%
2.06
Change In Account Payable
-0.09
+99.52%
-17.56
-170.92%
24.76
+1105.01%
2.06
Change In Other Working Capital
-3.44
+51.35%
-7.07
+57.86%
-16.77
-20.50%
-13.91
Change In Other Current Liabilities
-9.70
-271.80%
5.65
+1450.72%
-0.42
+74.02%
-1.61
Investing Cash Flow
27.89
-71.92%
99.33
+78.08%
55.78
+271.34%
-32.55
Cash Flow From Continuing Investing Activities
27.89
-71.92%
99.33
+165.51%
-151.63
-365.78%
-32.55
Cash From Discontinued Investing Activities
0.00
0.00
-100.00%
207.40
0.00
Net PPE Purchase And Sale
—
—
-0.67
-249.74%
-0.19
Purchase Of PPE
—
—
-0.67
-249.74%
-0.19
Capital Expenditure
-58.16
+42.54%
-101.21
-143.35%
-41.59
-46.62%
-28.37
Net Investment Purchase And Sale
86.45
-56.90%
200.58
+283.40%
-109.37
-3120.47%
-3.40
Purchase Of Investment
-237.14
-88.57%
-125.76
+71.67%
-443.94
-15.19%
-385.39
Sale Of Investment
323.60
-0.84%
326.33
-2.46%
334.57
-12.41%
381.99
Net Intangibles Purchase And Sale
-58.16
+42.54%
-101.21
-143.35%
-41.59
-46.62%
-28.37
Purchase Of Intangibles
-58.16
+42.54%
-101.21
-143.35%
-41.59
-46.62%
-28.37
Net Other Investing Changes
-0.40
-910.00%
-0.04
+94.01%
-0.67
+15.55%
-0.79
Financing Cash Flow
-33.47
-124.00%
139.42
-36.26%
218.75
+86.06%
117.57
Cash Flow From Continuing Financing Activities
-33.47
-124.00%
139.42
-36.66%
220.13
+83.37%
120.05
Net Issuance Payments Of Debt
-68.90
0.00
0.00
-100.00%
104.93
Issuance Of Debt
—
0.00
0.00
-100.00%
316.25
Repayment Of Debt
-68.90
0.00
0.00
+100.00%
-211.32
Long Term Debt Issuance
—
0.00
0.00
-100.00%
316.25
Long Term Debt Payments
-68.90
0.00
0.00
+100.00%
-211.32
Net Long Term Debt Issuance
-68.90
0.00
0.00
-100.00%
104.93
Net Common Stock Issuance
0.00
-100.00%
134.74
-29.53%
191.20
+878.25%
19.55
Proceeds From Stock Option Exercised
37.54
+453.32%
6.78
-78.14%
31.04
+310.37%
7.56
Net Other Financing Charges
-2.10
+0.00%
-2.10
+0.00%
-2.10
+82.47%
-11.98
Changes In Cash
32.21
+2432.15%
1.27
+123.16%
-5.49
+94.58%
-101.27
Effect Of Exchange Rate Changes
2.29
+350.93%
-0.91
-146.09%
1.98
+170.90%
-2.79
Beginning Cash Position
58.53
+0.62%
58.18
-5.69%
61.69
-62.78%
165.75
End Cash Position
93.03
+58.94%
58.53
+0.62%
58.18
-5.69%
61.69
Free Cash Flow
-20.37
+93.98%
-338.69
-5.31%
-321.61
-49.83%
-214.66
Interest Paid Supplemental Data
8.84
+0.00%
8.84
+0.00%
8.84
-13.00%
10.16
Income Tax Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-4.44
+2.18%
-4.54
+39.18%
-7.46
-965.14%
-0.70
Common Stock Issuance
0.00
-100.00%
134.74
-29.53%
191.20
+878.25%
19.55
Issuance Of Capital Stock
0.00
-100.00%
134.74
-29.53%
191.20
+878.25%
19.55
Cash From Discontinued Financing Activities
0.00
0.00
+100.00%
-1.38
+44.25%
-2.48
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category